Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | GAPDH | P04406 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25508926 | 0.74 | ACHE (0.35) | MAOBACHE | |
| SCHEMBL6884067 | 0.70 | KCNH2 (0.34) | MAOBMEN1KMT2AKCNH2 | |
| SCHEMBL6885791 | 0.69 | HTR2A (0.34) | MAOB | |
| SCHEMBL9627918 | 0.66 | IDO1 (0.61) | GAPDHPTPN1MEN1NSD2KMT2A | |
| SCHEMBL15026430 | 0.63 | IDO1 (0.61) | GAPDHPTPN1MEN1NSD2KMT2A | |
| SCHEMBL23836093 | 0.62 | MAOB (0.53) | MAOBMEN1KMT2AIDO1 | |
| SCHEMBL20371515 | 0.62 | MAOB (0.53) | MAOBMEN1KMT2AIDO1 | |
| SCHEMBL9642237 | 0.61 | MAPT (0.59) | PTPN1MEN1KMT2AL3MBTL1CDC25A | |
| SCHEMBL6885233 | 0.61 | SRD5A1 (0.46) | MAOBACHE | |
| SCHEMBL8355719 | 0.61 | SRD5A1 (0.46) | MAOBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3144296-A1 | DEUTERATED TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9273009-B2 | Tetrahydronaphthalene derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273009-B2 | Tetrahydronaphthalene derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140155444-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155444-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8575361-B2 | Tetrahydronaphthalene derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575361-B2 | Tetrahydronaphthalene derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8513434-B2 | Tetrahydronaphthalene derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513434-B2 | Tetrahydronaphthalene derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2013036434-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS T-TYPE CALCIUM CHANNEL BLOCKER | CONCERT PHARMACEUTICALS INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20120122944-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122944-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110237635-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237635-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011109464-A1 | DEUTERATED TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155444-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1H, CACNA1I, CACNA1G | MAOB 1249/4885GAPDH 3796/4885PTPN1 1761/4885 |
| US-20120122944-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1H, CACNA1I, CACNA1G | MAOB 1249/4885GAPDH 3796/4885PTPN1 1761/4885 |
| US-20110237635-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1H, CACNA1I, CACNA1G | MAOB 1249/4885GAPDH 3796/4885PTPN1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.